JeffreyLVacircaMD

Oncology • Port Jefferson, NY

Consultant in Oncology and Hematology

Join to view full profile

Dr. Vacirca is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Vacirca's full profile

Already have an account?

Office
1500 Route 112 Bldg. 4 Suite 101
Port Jefferson, NY 11776
Phone+1 631-751-3000
Is this information wrong?

Education & Training

Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 1998 - 2001
St. George's University School of MedicineClass of 1998

Certifications & Licensure

CT State Medical License 2019 - 2025
SC State Medical License 2019 - 2025
TN State Medical License 2019 - 2025
NJ State Medical License 2019 - 2025
NY State Medical License 2001 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Fellow (FACP) American College of Physicians, 2007

Clinical Trials

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 2
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Octagam 5% Versus Comparator Post Marketing Trial Start of enrollment: 2013 May 21
Completed
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Start of enrollment: 2014 Mar 01
Completed
Phase 3
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Start of enrollment: 2015 Dec 01
Completed
Join now to see all

Publications & Presentations

PubMed

Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
Martin Barnes, George Calcanes, Michael C Mosier, Jeffrey Vacirca, Zulfiqar Malik> ;American Health & Drug Benefits. 2021 Dec 1
Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
Martin Barnes, George Calcanes, Michael C Mosier, Jeffrey Vacirca, Zulfiqar Malik> ;American Health & Drug Benefits. 2021 Sep 1
Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data.
Celestia S. Higano, Andrew J. Armstrong, Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, David F. Penson, Neal...> ;Cancer. 2020 Jun 15
Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Mei Gao, Miranda Lin, Richard A. Moffitt, Marcela d'Alincourt Salazar, Jinha M. Park, Jeffrey Vacirca, Chuan Huang, Kenneth R. Shroyer, Minsig Choi, Georgios V. Georga...> ;British Journal of Cancer. 2020 May 11
45 citations
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
Celestia S. Higano, Andrew J. Armstrong, A. Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, David F. Penson, N...> ;Cancer. 2019 Dec 1
4 citations
Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.
George Calcanes, Jeffrey L. Vacirca> ;Journal of Infusion Nursing. 2019 Sep 1
29 citations
Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Mei Gao, Miranda Lin, Richard A. Moffitt, Marcela d'Alincourt Salazar, Jinha M. Park, Jeffrey Vacirca, Chuan Huang, Kenneth R. Shroyer, Minsig Choi, Georgios V. Georga...> ;British Journal of Cancer. 2019 Jan 1
9 citations
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai, Kimberly McGregor, Meena Okera, Zsolt Horváth, László Landherr, Jerzy Hanslik, Steven ...> ;Cancer Medicine. 2018 May 1
17 citations
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Valeriy Domenyuk, Zoran Gatalica, Radhika Santhanam, Xixi Wei, Adam Stark, Patrick Kennedy, Brandon Toussaint, Symon Levenberg, Jie Wang, Nianqing Xiao, Richard Greil,...> ;Nature Communications. 2018 Mar 23
9 citations
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Jeffrey L. Vacirca, Dennis Caruana, George Calcanes, Michael Mosier, Ralph V. Boccia, Ali McBride> ;Future Oncology. 2018 Feb 9
3 citations
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus...
Ian D. Schnadig, Richy Agajanian, Christopher Dakhil, Nashat Y. Gabrail, Jeffrey L. Vacirca, Charles J. Taylor, Sharon Wilks, Eduardo Braun, Michael Mosier, Robert B. ...> ;Cancer Management and Research. 2017 May 19
15 citations
Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.
Vincent J. Picozzi, Siva Narayanan, X. Henry Hu, Jeffrey Vacirca> ;Journal of Gastrointestinal Cancer. 2017 Mar 1
21 citations
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy
Ian D. Schnadig, Richy Agajanian, Christopher Dakhil, Nashat Y. Gabrail, Robert E. Smith, Charles J. Taylor, Sharon Wilks, Lee S. Schwartzberg, William Cooper, Michael...> ;Future Oncology. 2016 Mar 21
74 citations
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences
Kai Wang, Adrienne Johnson, Siraj M. Ali, Samuel J. Klempner, Tanios Bekaii-Saab, Jeffrey L. Vacirca, Depinder Khaira, Roman Yelensky, Juliann Chmielecki, Julia A. Elv...> ;The Oncologist. 2015 Oct 1
1 citations
Oncology Payment Reform and Drug Reimbursement in the Proper Perspective
Mark Thompson, Jeffrey Vacirca, Ted Okon> ;Journal of Oncology Practice. 2015 Mar 3
77 citations
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
Jeffrey Vacirca, Peter. I. Acs, Imad A. Tabbara, Peter Rosen, Peter P. Lee, Eric B. Lynam> ;Annals of Hematology. 2014 Mar 1
The authors respond.
Eagle D, Buell R, Vacirca J> ;Oncology (Williston Park, N.Y.). 2014-03-01
3 citations
The 340b Drug Discount Program: Oncology's Optical Illusion
David Eagle, Roberta L. Buell, Jeffrey Vacirca> ;Oncology. 2013 Nov 16
10 citations
Reversible posterior leukoencephalopathy syndrome after rituximab.
Joseph A. Zito, Christopher C. Lee, Scott Johnson, Adam J. Singer, Jeffrey Vacirca> ;The American Journal of Emergency Medicine. 2010 May 1
4 citations
The organomercurial 4-aminophenylmercuric acetate, independent of matrix metalloproteinases, induces dose-dependent activation/ inhibition of platelet aggregation
Mathias T. Rosenfeldt, Michael D. Valentino, Salvatore Labruzzo, Lesley E. Scudder, Maria Pavlaki, Jian Cao, Jeffrey Vacirca, Wadie F. Bahou, Stanley Zucker> ;Thrombosis and Haemostasis. 2005 Feb 1
389 citations
Role of matrix metalloproteinases (MMPs) in colorectal cancer.
Stanley Zucker, Jeffrey Vacirca> ;Cancer Metastasis Reviews. 2004 Jan 1
Join now to see all

Press Mentions

“It’s Crazy Money”: PBMs and the Need for TransparencyMarch 29th, 2023
Community Oncology: The Next 20 YearsMarch 25th, 2023
Annexus Health Raises $33 Million to Further Improve Patient Access and AffordabilityAugust 2nd, 2022
Join now to see all